Work

Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma

Year: 2019

Type: article

Study designs: Systematic Review, Meta-Analysis

Source: Clinical Genitourinary Cancer

DOI: 10.1016/j.clgc.2019.11.016

Authors: Andreas Varkaris, Wenxin Xu, Roger B. Davis, Brian Healy, David F. McDermott

Institutions: Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Harvard University

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Merck, Novartis, Harvard University, Harvard Catalyst, Exelixis, National Institutes of Health, Genentech, National Center for Research Resources, National Center for Advancing Translational Sciences

Award: The Harvard Clinical and Translational Science Center

OpenAlex ID: W2992077471

FWCI: 1.285

Cites: 23

Cited by: 14

Related to: 10